December 2nd 2024
Your daily dose of the clinical news you may have missed.
Impact of Effective BP Control in Reducing CV Risk in Patients with Obesity & HTN
November 20th 2023Patients with obesity and hypertension need to be aggressively treated in order to decrease their risk of cardiovascular complications, says Dr Jonathan Parker, President of the Alabama Obesity Society.
Semaglutide Cuts Cardiovascular Risk by 20% in Adults with Obesity, CVD and Without Diabetes
November 13th 2023AHA 2023: Semaglutide 2.4 mg reduced the risk of serious cardiovascular events by 20% in patients with obesity and overweight with established CVD but without diabetes, according to full SELECT trialresults.